10-May-2024
TherapeuticsMD Releases Preliminary Q1 2024 Financials
TipRanks (Fri, 10-May 4:34 PM ET)
Therapeutics MD GAAP EPS of -$0.07
Seeking Alpha News (Fri, 10-May 4:17 PM ET)
TherapeuticsMD Announces First Quarter 2024 Financial Results
Business Wire (Fri, 10-May 4:05 PM ET)
TherapeuticsMD Announces Full Year 2023 Financial Results
Business Wire (Fri, 29-Mar 4:00 PM ET)
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Therapeuticsmd trades on the NASDAQ stock market under the symbol TXMD.
As of May 10, 2024, TXMD stock price was flat at $2.03 with 4,769 million shares trading.
TXMD has a beta of 1.62, meaning it tends to be more sensitive to market movements. TXMD has a correlation of 0.10 to the broad based SPY ETF.
TXMD has a market cap of $21.47 million. This is considered a Sub-Micro Cap stock.
Last quarter Therapeuticsmd reported $-53,000 in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-553,000 and missed earnings estimates by -$.08.
In the last 3 years, TXMD stock traded as high as $69.50 and as low as $1.84.
The top ETF exchange traded funds that TXMD belongs to (by Net Assets): VTI, VXF, IWC.
TXMD has underperformed the market in the last year with a return of -47.5%, while the SPY ETF gained +27.8%. In the last 3 month period, TXMD fell short of the market, returning -11.4%, while SPY returned +4.2%. However, in the most recent 2 weeks TXMD has outperformed the stock market by returning +9.1%, while SPY returned +2.5%.
TXMD support price is $1.94 and resistance is $2.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TXMD stock will trade within this expected range on the day.